11 results about "Prostatic tissue" patented technology

The application discloses application of a reagent for detecting AHSP protein in preparation of a product for diagnosing prostate cancer, and relates to the technical field of biological medicine; through proteomic analysis, ELISA test on urine protein of prostate cancer patients, clear cell renal cell carcinoma patients and normal healthy men, and immunohistochemical analysis on file wax blocks of the prostate cancer patients, normal prostate tissues around the cancer, prostate tissues of prostatic hyperplasia and clear cell renal cell carcinoma tissues, it is found that the AHSP protein has a certain relationship with the occurrence and development of prostate cancer, and can be used for assisting diagnosis of the prostate cancer; and in urine detection, AHSP has higher sensitivity than PSA, and when PSA is negative or serum PSA is low, AHSP can form complementation with ASHP, thereby helping to improve the diagnosis rate and non-invasive screening ability; through research on the relationship between the AHSP protein and the prostate cancer, the diagnosis rate of patients can be improved, non-invasive reexamination after treatment is facilitated, drug use is guided, and the survival rate is improved.

The use of a Reyanning formulation in the preparation of a drug for preventing and treating prostatitis. The Reyanning formulation is prepared from dandelion, giant knotweed rhizome, sonchi arvensis herba and herba scutellariae barbatae. The present application finds that the Reyanning formulation can reduce the contents of IL-6, IL-1β, NO and MDA in the serum of model rats, HE staining results show that the Reyanning formulation has certain relieving effect on the damage of prostate tissue, and it can be concluded from the molecular and tissue levels that the Reyanning formulation has certain prevention and treatment effect on chronic non-bacterial prostatitis.

Devices and systems are disclosed for managing and / or treating body tissues obstructing a hollow body lumen, including the prostatic lobe tissues obstructing the urethra, for example conditions including benign prostatic hyperplasia (BPH), bladder outlet obstruction (BOO), benign prostatic obstruction (BPO) and associated lower urinary tract symptoms (LUTS). An implant is maintained in a constrained configuration within a distal portion of an elongated sheath so that is may be deployed by driving the implant with a pusher coaxially disposed within the sheath. An implant engaging element helps maintain control of the implant during deployment.

This invention discloses the application of SNCG protein in the auxiliary diagnosis of prostate cancer, belonging to the field of biomedical technology. The application involves using reagents specifically designed to detect SNCG protein expression in biological samples to prepare products for the auxiliary diagnosis of prostate cancer. Through proteomic analysis of urinary proteins from prostate cancer patients and normal men, this invention revealed that the concentration of SNCG protein in the urine of prostate cancer patients was significantly higher than that in the normal male group. Immunohistochemical analysis of paraffin-embedded tissue samples from prostate cancer patients and surrounding normal prostate tissue showed that SNCG protein has a certain expression rate in prostate cancer, and that SNCG protein is also expressed in the basal cells of normal prostate glands, indicating a certain relationship between SNCG protein and the occurrence and development of prostate cancer. This invention can be used to assist in the diagnosis of prostate cancer and difficult cases, thereby improving the diagnosis rate and survival rate of patients.

Implantable devices for retracting prostatic tissue of a patient are provided. In some embodiments, an implantable device may include a main body and a suture extending through at least a portion of the main body. The main body may be configured to extend through prostatic tissue of the patient such that a distal end portion of the main body resides at least partially outside of a prostatic capsule of the patient, and the distal end portion may be configured to deform from an undeformed configuration to a deformed configuration. The suture may include a first end and a second end extending from a proximal end of the main body, and the suture may be configured to cause the distal end portion to deform from the undeformed configuration to the deformed configuration when the first end and the second end are pulled proximally relative to the main body.

The application discloses a prostate puncture gun head for in-situ rotary cutting and a sampling method thereof, and belongs to the technical field of urological surgery. The needle head is arranged at the front end of the puncture gun and is used for penetrating into the prostate tissue; the blade groove is semicircular and is arranged along the longitudinal direction of the needle head; the blade is rotatably arranged in the blade groove and rotates along the track of the blade groove; the tissue groove is arranged on the surface of the needle head and is used for collecting the cut tissue sample; the knob spring device is connected with the blade and is used for providing rotary power to drive the blade to rotate and cut the prostate tissue along the blade groove. The knob spring device is used for driving the blade to rotate and move along the track of the semicircular blade groove, in-situ rotary cutting and sampling of the prostate tissue are realized, tissue tearing is effectively reduced, the flatness of the cutting surface is ensured, and the accuracy and efficiency of the sampling process are improved.

This invention discloses a prostate balloon dilation catheter, comprising a catheter body; a first balloon disposed outside the catheter body; and a blunt scoring body disposed along the axial direction of the first balloon on its surface, protruding from the surface of the first balloon, the blunt scoring body being used to press against a target location; wherein, in the uninflated state of the first balloon, the blunt scoring body is located at the fold position of the first balloon, the fold being a circumferential depression of the first balloon. This invention utilizes the blunt scoring body to press against the prostate tissue, creating stress concentration and thus assisting the anterior balloon in dilating the prostate at the target location. Compared to existing technologies, this effectively avoids the risk of scratches to the balloon and urethral wall.

This invention discloses a large-section kit for pathological prostate tissue, comprising an embedding cassette, an embedding mold, and a sample holder disposed within a storage box. The embedding cassette includes an embedding cassette body, a first partition, a first elastic clamping device, an embedding cassette lid, and a mounting ring. The bottom plate of the embedding cassette body, the embedding cassette lid, and the first partition are all plate structures with mesh openings. The pathologically obtained prostate tissue is placed between the first partition and the bottom plate of the embedding cassette body, and the elastic clamping device is disposed between the first partition and the embedding cassette lid. The embedding mold includes an embedding mold body, a second partition, and a second elastic clamping device. This invention can effectively improve the integrity and consistency of slide preparation, reduce specimen loss, and ensure the homogeneity of continuous step slides. Based on this, various specific staining methods can be performed, improving the reliability of pathological clinical diagnostic assessment and the objectivity of biological information diversity analysis in basic research, thereby reflecting the reliability of the gold standard for pathological testing.

Disclosed is a “benign prostatic hyperplasia surgical device using an anchor assembly and a needle. The benign prostatic hyperplasia surgical device includes a plurality of anchors disposed on the prostate gland compressing the urethra and a ligature thread connecting the plurality of anchors to each other so that the plurality of anchors continuously compress prostatic tissues to allow the urethra to be open. Further, the benign prostatic hyperplasia surgical device of the present invention includes: an elastic needle receiving the plurality of anchors therein and inserted into the urethra to guide the plurality of anchors and the ligature thread so that the plurality of anchors and the ligature thread are located on the prostate gland; and a needle launching means for launching the needle so that the needle is inserted into the urethra to allow the plurality of anchors and the ligature thread to be discharged through the needle.

The disclosure relates to compositions and methods for rAAV-mediated delivery of a transgene to a subject. In some embodiments, the rAAV transduces the prostate tissue of a subject. In some embodiments, the methods are useful for treatment of prostate disease (e.g., prostatitis, BPH, prostate cancer).

This invention discloses the application of reagents for detecting REEP protein in the preparation of products for diagnosing prostate cancer, relating to the field of biomedical technology. Through proteomic analysis, ELISA assays, and immunohistochemical analysis of urinary proteins from prostate cancer patients, clear cell renal cell carcinoma patients, urothelial carcinoma patients, and healthy individuals, as well as paraffin-embedded tissue samples from prostate cancer patients and surrounding normal prostate tissue, urothelial carcinoma tissue, and clear cell renal cell carcinoma tissue, it was found that REEP6 and REEP5 proteins are related to the occurrence and development of prostate cancer and can be used to assist in the diagnosis of prostate cancer. Furthermore, in urinary testing, REEP6 and REEP5 have higher sensitivity compared to PSA, and the three proteins can complement each other, thus helping to improve the diagnostic rate and non-invasive screening capabilities. Research on the relationship between REEP6 and REEP5 proteins and prostate cancer facilitates non-invasive follow-up after treatment and guides medication, thereby improving survival rates.